BBIO BridgeBio Pharma, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
19:48
Aug 31
Aug 31
BridgeBio Pharma agrees with the U.S. government to expand Medicaid and Medicare Part D access.
BridgeBio Pharma agrees with the U.S. government to expand Medicaid and Medicare Part D access to Attruby without future pricing mandates.
22:22
Aug 18
Aug 18
Author confirms holding Cytokinetics since 2024 and added at $82.80.
Author confirms holding Cytokinetics since 2024 and added at $82.80, while listing other long ideas and short candidates from a prior post without explicit current positioning.
13:09
Aug 17
Aug 17
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
LOW
13:05
Aug 17
Aug 17
Shares options positioning net conviction data.
Shares options positioning data showing net conviction based on fund holdings, no directional view.
MED
12:56
Aug 17
Aug 17
Reports heaviest selling across specialist funds
"Reports net conviction laggards with heaviest genuine selling across specialist funds in Q2 2026, no directional view."
MED
12:50
Aug 17
Aug 17
Reports most reduced positions across funds
"Reports most reduced positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
MED
12:32
Aug 17
Aug 17
Notes Q2 aggregate fund value decrease
Notes the stock saw one of the largest aggregate value decreases across 93 funds in Q2 13F filings.
MED
11:53
Aug 17
Aug 17
Reports most reduced positions by specialist funds
Reports the most reduced positions by specialist funds in Q2 2026, excluding M&A takeouts.
MED
12:13
Jul 09
Jul 09
Premarket movers report shows mixed Mag 7 stocks.
Premarket movers report shows mixed Mag 7 stocks, with notable gains for CECO on JPMorgan initiation, ALNY and BBIO on rival drug trial failure, and SMPL on earnings beat, while IBM, IONS, LEVI, MAT, and CRM decline on various negative catalysts.
01:54
Jul 01
Jul 01
Sixth Street Partners and KKR have agreed to provide one billion dollars of preferred equity.
Sixth Street Partners and KKR have agreed to provide one billion dollars of preferred equity to BridgeBio Pharma according to people with knowledge of the matter.
17:04
May 30
May 30
The author notes that the 6-minute walk test is a risky endpoint that can fail even.
The author notes that the 6-minute walk test is a risky endpoint that can fail even for effective drugs, using BBIO as an example without taking a position.
LOW
15:09
May 29
May 29
The author highlights Chris Staral's past holdings and return under Triple Helix.
The author highlights Chris Staral's past holdings and return under Triple Helix, but this is a historical research summary and watchlist, not an active position or forward call.
LOW
17:44
May 07
May 07
The author lays out a concentrated long biotech portfolio on a down XBI day.
The author lays out a concentrated long biotech portfolio on a down XBI day, highlighting ABVX as a major position and listing other names under consideration, reflecting a bullish sector outlook despite short-term losses.
HIGH
About BBIO Analyst Coverage
Buzzberg tracks BBIO (BridgeBio Pharma, Inc.) across 5 sources. 0 bullish vs 0 bearish calls from 5 analysts. Sentiment: evenly split. 13 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: FirstSquawk, seedy19tron, zerohedge.